Oral Abstract Session

 
 
Kazuhiro Yoshida, Yasuhiro Kodera, Mitsugu Kochi, et al.
 
The authors conclude:  
Adjuvant S-1 plus docetaxel is recommended for patients with pStage III gastric cancer who underwent D2 gastrectomy without neoadjuvant chemotherapy. Clinical trial information: UMIN 000010337.
 
 
Zev A. Wainberg, Peter C. Enzinger, Yoon-Koo Kang,
 
The authors conclude:  
Approximately 30% of 1L pts with advanced GC not HER2+, were identified to be FGFR2b+, primarily by IHC. In this randomized, placebo controlled, double-blind phase 2 study, the addition of bema to mFOLFOX6 led to clinically meaningful and statistically significant improvements in PFS, OS and ORR. An increase in corneal AEs and stomatitis was associated with bema. These results support a prospective randomized phase 3 study in GC and the evaluation of bema in other FGFR2b+ tumor types.
 
 
Yu Sunakawa, Ryo Matoba, Eisuke Inoue, et al.
 
The authors conclude:   
Our translational study indicated for the first time that bacterial invasion of epithelial cells pathway in gut microbiome may potentially become a novel biomarker for treatment with Nivo in advanced GC. In addition, we found gastric cancer-specific gut microbiome to predict response to immune checkpoint inhibitors. Clinical trial information: UMIN000030850.
 
 
Kazuo Koyanagi, Ken Kato, Yoshinori Ito, et al.
 
The authors conclude:  
Preoperative DCF and CF-RT does not increase the risk of perioperative complications and mortality when compared with standard preoperative CF therapy, but CF-RT increases the risk of chylothorax after esophagectomy for advanced thoracic esophageal cancer.
 
 

Rapid Abstract Session

 
 
Funda Meric-Bernstam, Erika P. Hamilton, Muralidhar Beeram, et al
 
The authors conclude:  
Zanidatamab, both as a single agent and in combination with chemotherapy, is well tolerated with promising and durable anti-tumor activity in heavily pretreated GEA patients (including prior HER2-targeted therapy). These data support further investigation of zanidatamab as a novel therapeutic for patients with HER2-expressing GEA.
 
 
Vanita Noronha, Vijay M. Patil, Amit Joshi, et al.
 
The authors conclude:   
Adjuvant oral metronomic chemotherapy after radical CRT does not improve outcomes in patients with locally advanced esophageal or GEJ squamous cell carcinoma. Clinical trial information: CTRI/2015/09/006204.
 
 
Daryl Chia, Raghav Sundar, Guo Wei Kim, et al.
 
The authors conclude:
IP PTX with XELOX is a promising treatment option for GCPM patients. For patients with good response, conversion surgery was feasible with favourable outcomes.
 
The authors conclude:   
Esophagectomy for malignancy had a similar perioperative safety profile and positive margin rate among general and thoracic surgeons, regardless of surgical approach.
 
The authors conclude:   
Preliminary results from CheckMate 577 demonstrated that pts on NIVO treatment showed trends of improvement in both esophageal-specific and general HRQoL. Similar trends were also observed in pts treated with PBO over 1 year. Pts treated with NIVO did not experience a reduction in HRQoL, further supporting clinical data to demonstrate treatment benefit and tolerability for adjuvant NIVO in pts with resected EC/GEJC.
 
The authors conclude:     
HRQoL was stable and similar over 18 weeks in the pembro + chemo and chemo arms. Together with superior OS, PFS, and ORR and a manageable safety profile with pembro + chemo, these results support the clinically meaningful benefit of pembro + chemo in patients with advanced esophageal cancer including EGJ adenocarcinoma.